Výsledky vyhľadávania - "Peters, Solange"

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Autori: Schmid, Dominic Sobottka, Bettina Manzo, Massimiliano a ďalší

Zdroj: Nature Communications; 9/30/2025, Vol. 16 Issue 1, p1-15, 15p

Predmety: NON-small-cell lung carcinoma, NEOADJUVANT chemotherapy, TREATMENT effectiveness, BIOMARKERS, TUMOR microenvironment, T cell receptors, PROGRESSION-free survival, T-cell exhaustion

Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1 , or KRAS : the TRITON study

Autori: Skoulidis, Ferdinandos Borghaei, Hossein Garon, Edward B. a ďalší

Zdroj: Therapeutic Advances in Medical Oncology; 11/6/2025, Vol. 17, p1-13, 13p

Proceedings of the 1st biannual bridging the gaps in lung cancer conference.

Autori: Florez, Narjust Patel, Sandip P Wakelee, Heather a ďalší

Zdroj: Oncologist; Feb2025, Vol. 30 Issue 2, p1-9, 9p

Predmety: RISK assessment, GENOMICS, IMMUNOTHERAPY, EARLY detection of cancer, TUMOR markers, TREATMENT effectiveness, DECISION making in clinical medicine, CONFERENCES & conventions, MINIMALLY invasive procedures, LUNG tumors, ONCOGENES, LUNG cancer, GENETIC mutation, TUMOR classification

Geografický termín: UNITED States

Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary.

Autori: de Langen, Adrianus Johannes Johnson, Melissa L. Mazieres, Julien a ďalší

Zdroj: Future Oncology; Apr2025, Vol. 21 Issue 9, p1033-1044, 12p

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.

Autori: Joo, Victor Abdelhamid, Karim Noto, Alessandra a ďalší

Zdroj: Nature Communications; 4/30/2024, Vol. 15 Issue 1, p1-12, 12p

Predmety: T cells, HEART transplantation, SQUAMOUS cell carcinoma, IMMUNE response, CELL physiology, GRAFT rejection

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.

Autori: Lim, Sun Min Peters, Solange Ortega Granados, Ana Laura a ďalší

Zdroj: Nature Communications; 11/11/2023, Vol. 14 Issue 1, p1-12, 12p

Predmety: CARBOPLATIN, NON-small-cell lung carcinoma, METASTASIS, CANCER chemotherapy, PEMETREXED

Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study.

Autori: Jolidon, Vladimir Eicher, Manuela Peytremann‐Bridevaux, Isabelle a ďalší

Zdroj: Cancer (0008543X); 12/15/2024, Vol. 130 Issue 24, p4334-4346, 13p

Predmety: PATIENT experience, PATIENT satisfaction, PATIENTS' attitudes, CANCER treatment, ODDS ratio, CANCER patient care

Calls to action on lung cancer management and research.

Autori: Meyer, May-Lucie Hirsch, Fred R Bunn, Paul A a ďalší

Zdroj: Oncologist; Dec2024, Vol. 29 Issue 12, pe1634-e1645, 12p

Predmety: TREATMENT of lung tumors, SMOKING cessation, INTERPROFESSIONAL relations, DISEASE management, CLINICAL medicine research, EARLY detection of cancer, IMMUNOTHERAPY, TUMOR markers, PUBLIC health

Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?

Autori: Desai, Aakash Subbiah, Vivek Roy-Chowdhuri, Sinchita a ďalší

Zdroj: Cancers; Nov2024, Vol. 16 Issue 22, p3753, 8p

Predmety: TISSUE analysis, PREVENTION of drug side effects, RISK assessment, MEDICAL information storage & retrieval systems, ANTINEOPLASTIC agents, IMMUNOGLOBULINS, INTERSTITIAL lung diseases, LUNGS, GENE expression, SYSTEMATIC reviews, MEDLINE, RNA probes, CAUSALITY (Physics), GENE expression profiling, MEDICAL databases, LUNG cancer, TUMOR antigens, DISEASE risk factors

A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.

Autori: Bandiera, Carole Cardoso, Evelina Locatelli, Isabella a ďalší

Zdroj: PLoS ONE; 6/7/2024, Vol. 19 Issue 6, p1-22, 22p

Predmety: PATIENT compliance, PROTEIN kinase inhibitors, GENERALIZED estimating equations, ELECTRONIC feedback, PHARMACIST-patient relationships

Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis.

Autori: Kinj, Rémy Hottinger, Andreas Felix Böhlen, Till Tobias a ďalší

Zdroj: Cancers; May2024, Vol. 16 Issue 9, p1742, 12p

Predmety: BRAIN tumor diagnosis, RESEARCH funding, RADIOSURGERY, MAGNETIC resonance imaging, DESCRIPTIVE statistics, METASTASIS, LONGITUDINAL method, LUNG cancer, OVERALL survival

Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib.

Alternate Title: Verzögerte Diagnose eines Lungenkarzinoms, das sich als choroidale Metastase in einem COVID-19-Patienten präsentierte und am Anfang mit Osimertinib behandelt wurde. (German)

Autori: Haeller, Celine Noha Khamsy, Lilly Kloepper, Jonas a ďalší

Zdroj: Klinische Monatsblätter für Augenheilkunde; Apr2022, Vol. 239 Issue 4, p586-589, 4p

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study: Findings From the PACIFIC-R Study

Autori: Girard, Nicolas Bar, Jair Garrido, Pilar a ďalší

Prispievatelia: Girard, Nicolas Bar, Jair Garrido, Pilar a ďalší

Zdroj: Journal of thoracic oncology, vol. 18, no. 2, pp. 181-193

Predmety: 0301 basic medicine, Lung Neoplasms, Locally advanced NSCLC, [SDV.CAN]Life Sciences [q-bio]/Cancer, Chemoradiotherapy, Ligands, 16. Peace & justice, Real-world data, Progression-Free Survival, 3. Good health, Cohort Studies, 03 medical and health sciences, Humans, Antineoplastic Agents, Immunological/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Lung Neoplasms/drug therapy, Retrospective Studies, Consolidation therapy, Immunotherapy, PD-L1 inhibition, Antineoplastic Agents, Immunological, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Carcinoma, Non-Small-Cell Lung

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36307040
https://research.rug.nl/en/publications/bb365b94-613a-4c92-9e5a-453545a119de
https://hdl.handle.net/11370/bb365b94-613a-4c92-9e5a-453545a119de
https://doi.org/10.1016/j.jtho.2022.10.003
https://hal.science/hal-04122372v1
https://hal.science/hal-04122372v1/document
https://doi.org/10.1016/j.jtho.2022.10.003
https://serval.unil.ch/notice/serval:BIB_D36FA0602240
https://serval.unil.ch/resource/serval:BIB_D36FA0602240.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_D36FA06022404

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges

Autori: Mountzios, Giannis Remon, Jordi Hendriks, Lizza E. L. a ďalší

Zdroj: Nature Reviews Clinical Oncology vol.20 (2023) nr.10 p.664-677 [ISSN 1759-4774]

Témy: PLATINUM-DOUBLET CHEMOTHERAPY, NEOADJUVANT CHEMOTHERAPY, PHASE-III, ADJUVANT CHEMOTHERAPY, OPEN-LABEL, PATHOLOGICAL RESPONSE, DOCETAXEL-CISPLATIN, SUPPORTIVE CARE, POOLED ANALYSIS, SINGLE-CENTER, (Systematic) Review article

URL: https://cris.maastrichtuniversity.nl/en/publications/6645882b-514d-48a7-841a-0c82e0f58a4f
https://cris.maastrichtuniversity.nl/ws/files/225313593/Hendriks-2024-Immune-checkpoint-inhibition-for-resectable.pdf
https://cris.maastrichtuniversity.nl/ws/files/225313593/Hendriks-2024-Immune-checkpoint-inhibition-for-resectable.pdf

Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer.

Autori: Dómine Gómez, Manuel Subbiah, Vivek Peters, Solange a ďalší

Zdroj: Expert Review of Anticancer Therapy; Jan2025, Vol. 25 Issue 1, p27-40, 14p

Predmety: SMALL cell lung cancer, GRANULOCYTE-colony stimulating factor, DRUG resistance in cancer cells, TREATMENT effectiveness, PLATINUM

Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations: A Review.

Autori: Passaro, Antonio Mok, Tony S. K. Attili, Ilaria a ďalší

Zdroj: JAMA Oncology; Aug2023, Vol. 9 Issue 8, p1124-1131, 8p

Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies.

Autori: Bajpai, Jyoti Mailankody, Sharada Garrido, Pilar a ďalší

Zdroj: Indian Journal of Medical & Paediatric Oncology; 2022, Vol. 43 Issue 1, p4-7, 4p

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.

Autori: Budczies, Jan Kirchner, Martina Kluck, Klaus a ďalší

Zdroj: Cancer Immunology, Immunotherapy; Feb2022, Vol. 71 Issue 2, p251-265, 15p

Predmety: TUMOR microenvironment, REGULATORY T cells, GENE expression profiling, IMMUNE checkpoint proteins, GENE expression

The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.

Autori: Shapira-Frommer, Ronnie Niu, Jiaxin Perets, Ruth a ďalší

Zdroj: Future Oncology; 2024, Vol. 20 Issue 27, p1983-1991, 9p

Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance.

Autori: Hwang, Michael Chia, Yen Lin Zheng, Yanan a ďalší

Zdroj: British Journal of Clinical Pharmacology; May2023, Vol. 89 Issue 5, p1601-1616, 16p

Predmety: MONOCLONAL antibodies, PHARMACOKINETICS, EXPOSURE dose, TUMORS, CANCER patients, ALBUMINS